Your browser doesn't support javascript.
Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus.
Elibol, Ayça; Eren, Didem; Erdogan, Macide Deniz; Elmaagaç, Merve; Dizdar, Oguzhan Sitki; Çelik, Ilhami; Günal, Ali Ihsan.
  • Elibol A; University of Health Sciences Kayseri City Training and Research Hospital, Department of Internal Medicine, Kayseri, Turkey.
  • Eren D; University of Health Sciences Kayseri City Training and Research Hospital, Department of Internal Medicine, Kayseri, Turkey.
  • Erdogan MD; University of Health Sciences Kayseri City Training and Research Hospital, Department of Internal Medicine, Kayseri, Turkey.
  • Elmaagaç M; University of Health Sciences Kayseri City Training and Research Hospital, Department of Internal Medicine, Kayseri, Turkey.
  • Dizdar OS; University of Health Sciences Kayseri City Training and Research Hospital, Department of Internal Medicine, Kayseri, Turkey. Electronic address: oguzhansitki.dizdar@sbu.edu.tr.
  • Çelik I; University of Health Sciences Kayseri City Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Kayseri, Turkey.
  • Günal AI; University of Health Sciences Kayseri City Training and Research Hospital, Department of Nephrology, Kayseri, Turkey.
Prim Care Diabetes ; 15(5): 806-812, 2021 10.
Article in English | MEDLINE | ID: covidwho-1340786
ABSTRACT

BACKGROUND:

Diabetes mellitus (DM) increases mortality and morbidity in patients with coronavirus disease (COVID-19). In this study, it was aimed to assess factors influencing on COVID-19 pneumonia in hospitalized patients with diabetes and association with oral anti-diabetic drugs. MATERIALS AND

METHODS:

This cross-sectional study included 432 patients with type 2 diabetes mellitus diagnosed with COVID-19. Data regarding clinical characteristics, demographic characteristics, intensive care unit (ICU) rate in patients admitted to ICU, laboratory results on day 1 and 7, thoracic computed tomography (CT) findings and oral anti-diabetic drugs used were extracted from medical records. In all patients, 75-days mortality was recorded. Data were assessed independently.

RESULTS:

There was pneumonia in 386 (89.4%) of 432 patients with diabetes. The risk for pneumonia was markedly higher in patients on DPP-4 inhibitors; however, there was no significant among other oral anti-diabetic groups and subgroups. In addition, elevated CRP was linked to the increased risk for pneumonia. Only patients in the pneumonia group had SGLT-2 inhibitor use. During follow-up, 91 patients died. In Cox regression analysis, low Glasgow Coma Scale score, and increased lactate dehydrogenase levels were identified as significant independent risk factors for mortality.

CONCLUSION:

The study indicated that DPP-4 inhibitor used and elevated CRP level were associated with pneumonia development. Only patients in the pneumonia group had SGLT-2 inhibitor use. No oral anti-diabetics was found to be associated with COVID-19 related death.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmaceutical Preparations / Diabetes Mellitus, Type 2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Prim Care Diabetes Journal subject: Endocrinology Year: 2021 Document Type: Article Affiliation country: J.pcd.2021.08.001

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmaceutical Preparations / Diabetes Mellitus, Type 2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Prim Care Diabetes Journal subject: Endocrinology Year: 2021 Document Type: Article Affiliation country: J.pcd.2021.08.001